Antitumor mechanisms of systemically administered epidermal growth factor receptor antisense oligonucleotides in combination with docetaxel in squamous cell carcinoma of the head and neck

Molecular Pharmacology

Volumn 73, Issue 3, 2008, Pages 627-638

  Thomas, Sufi Mary ^a,d   Ogagan, Michelene Jeter ^a   Freilino, Maria L ^a   Strychor, Sandy ^b   Walsh, Dustin R ^b   Gooding, William E ^c   Grandis, Jennifer Rubin ^a,b   Zamboni, William C ^b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURGERY; CELL PROLIFERATION; COMPARATIVE STUDY; CONTROL GROUP; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; HEAD AND NECK CARCINOMA; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE DRUG DOSE; SQUAMOUS CELL CARCINOMA; TREATMENT DURATION; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; INJECTIONS, INTRAPERITONEAL; MICE; MICE, NUDE; MODELS, BIOLOGICAL; OLIGONUCLEOTIDES, ANTISENSE; ONCOGENE PROTEIN V-AKT; RANDOM ALLOCATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; STATISTICS AS TOPIC; TAXOIDS; TIME FACTORS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 40849100332     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.107.041160     Document Type: Article

References (39)

1. Agrawal S (1996) Antisense oligonucleotides: towards clinical trials. Trends Biotechnol 14:376-387. 8987636
2. Beltinger C, Saragovi HU, Smith RM, LeSauteur L, Shah N, DeDionisio L, Christensen L, Raible A, Jarett L, and Gewirtz AM (1995) Binding, uptake, and intracellular trafficking of phosphorothioate-modified oligodeoxynucleotides. J Clin Invest 95:1814-1823. 7706488
3. Bissery MC, Nohynek G, Sanderink GJ, and Lavelle F (1995) Docetaxel (Taxotere): a review of preclinical and clinical experience. Part I: preclinical experience. Anticancer Drugs 6:339-355, 363-338.
4. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, et al. (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567-578. 16467544
5. Chen HX, Marshall JL, Ness E, Martin RR, Dvorchik B, Rizvi N, Marquis J, McKinlay M, Dahut W, and Hawkins MJ (2000) A safety and pharmacokinetic study of a mixed-backbone oligonucleotide (GEM231) targeting the type I protein kinase A by two-hour infusions in patients with refractory solid tumors. Clin Cancer Res 6:1259-1266. 10778949
6. Ciardiello F, Caputo R, Bianco R, Damiano V, Pomatico G, De Placido S, Bianco AR, and Tortora G (2000) Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptorselective tyrosine kinase inhibitor. Clin Cancer Res 6:2053-2063. 10815932
7. Clarke SJ and Rivory LP (1999) Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet 36:99-114. 10092957
8. Dreyfuss AI, Clark JR, Norris CM, Rossi RM, Lucarini JW, Busse PM, Poulin MD, Thornhill L, Costello R, and Posner MR (1996) Docetaxel: an active drug for squamous cell carcinoma of the head and neck. J Clin Oncol 14:1672-1678. 8622087
9. Eder PS, DeVine RJ, Dagle JM, and Walder JA (1991) Substrate specificity and kinetics of degradation of antisense oligonucleotides by a 3′ exonuclease in plasma. Antisense Res Dev 1:141-151. 1841656
10. Edwards D and Berry JJ (1987) The efficiency of simulation-based multiple comparisons. Biometrics 43:913-928. 3427176
11. Gao WY, Storm C, Egan W, and Cheng YC (1993) Cellular pharmacology of phosphorothioate homooligodeoxynucleotides in human cells. Mol Pharmacol 43:45-50. 8423768
12. Grandis JR, Chakraborty A, Zeng Q, Melhem MF, and Tweardy DJ (1998) Down-modulation of TGF-alpha protein expression with antisense oligonucleotides inhibits proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells. J Cell Biochem 69:55-62. 9513046
13. He Y, Zeng Q, Drenning SD, Melhem MF, Tweardy DJ, Huang L, and Grandis JR (1998) EGFR antisense RNA transcribed from the U6 promotor inhibits human squamous cell carcinoma growth in vivo. J Natl Cancer Inst 90:1080-1087. 9672256
14. Heo DS, Snyderman C, Gollin SM, Pan S, Walker E, Deka R, Barnes EL, Johnson JT, Herberman RB, and Whiteside TL (1989) Biology, cytogenetics, and sensitivity to immunological effector cells of new head and neck squamous cell carcinoma lines. Cancer Res 49:5167-5175. 2766286
15. Herbst RS, O'Neill VJ, Fehrenbacher L, Belani CP, Bonomi PD, Hart L, Melnyk O, Ramies D, Lin M, and Sandler A (2007) Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non-small-cell lung cancer. J Clin Oncol 25:4743-4750. 17909199
16. Higgins B, Kolinsky K, Smith M, Beck G, Rashed M, Adames V, Linn M, Wheeldon E, Gand L, Birnboeck H, et al. (2004) Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models. Anticancer Drugs 15:503-512. 15166626
17. Hu Y, Cherton-Horvat G, Dragowska V, Baird S, Korneluk RG, Durkin JP, Mayer LD, and LaCasse EC (2003) Antisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lung cancer cells in vitro and in vivo. Clin Cancer Res 9:2826-2836. 12855663
18. Jain RK (1998) The next frontier of molecular medicine: delivery of therapeutics. Nat Med 4:655-657. 9623964
19. Jain RK (2001) Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 7:987-989. 11533692
20. McDonald DM and Baluk P (2002) Significance of blood vessel leakiness in cancer. Cancer Res 62:5381-5385. 12235011
21. Mendelsohn J (2001) The epidermal growth factor receptor as a target for cancer therapy. Endocr Relat Cancer 8:3-9. 11350723
22. Ng SS, Tsao MS, Nicklee T, and Hedley DW (2002) Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma. Mol Cancer Ther 1:777-783. 12492110
23. Niwa H, Wentzel AL, Li M, Gooding WE, Lui VW, and Grandis JR (2003) Antitumor effects of epidermal growth factor receptor antisense oligonucleotides in combination with docetaxel in squamous cell carcinoma of the head and neck. Clin Cancer Res 9:5028-5035. 14581378
24. Parise RA, Ramanathan RK, Zamboni WC, and Egorin MJ (2003) Sensitive liquid chromatography-mass spectrometry assay for quantitation of docetaxel and paclitaxel in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 783: 231-236. 12450543
25. Rubin Grandis J, Chakraborty A, Melhem MF, Zeng Q, and Tweardy DJ (1997) Inhibition of epidermal growth factor receptor gene expression and function decreases proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells. Oncogene 15:409-416. 9242377
26. Sacks PG, Parnes SM, Gallick GE, Mansouri Z, Lichtner R, Satya-Prakash KL, Pathak S, and Parsons DF (1988) Establishment and characterization of two new squamous cell carcinoma cell lines derived from tumors of the head and neck. Cancer Res 48:2858-2866. 2452013
27. Schöffski P, Catimel G, Planting AS, Droz JP, Verweij J, Schrijvers D, Gras L, Schrijvers A, Wanders J, and Hanauske AR (1999) Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Clinical Studies Group. Ann Oncol 10:119-122. 10076732
28. Sparreboom A, van Tellingen O, Nooijen WJ, and Beijnen JH (1998) Preclinical pharmacokinetics of paclitaxel and docetaxel. Anticancer Drugs 9:1-17. 9491787
29. Strychor SEJ, Parise RA, Egorin MJ, Joseph E, and Zamboni WC (2005) Plasma, tumor, and tissue disposition of docetaxel in SCID mice bearing SKOV-3 human ovarian xenografts, in Proceedings of the American Association for Cancer Research; 2005 April 16-20; Anaheim, CA. Vol. 46, pp 938, American Association for Cancer Research, Philadelphia, PA.
30. Thomas SM and Grandis JR (2004) Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation. Cancer Treat Rev 30:255-268. 15059649
31. Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, and Jain RK (2004) Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 64:3731-3736. 15172975
32. Uehara HKS, Karashima T, Zheng L, and Fidler IJ (2001) Blockade of PDGF-R signaling by STI-571 inhibits angiogenesis and growth of human prostate cancer cells in the bone of nude mice, in Proceedings of the American Association for Cancer Research; 2001 March 24-28; New Orleans, LA. Vol. 46, pp 407, American Association for Cancer Research, Philadephia, PA.
33. Viloria-Petit A, Crombet T, Jothy S, Hicklin D, Bohlen P, Schlaeppi JM, Rak J, and Kerbel RS (2001) Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res 61:5090-5101. 11431346
34. Wang H, Hang J, Shi Z, Li M, Yu D, Kandimalla ER, Agrawal S, and Zhang R (2002) Antisense oligonucleotide targeted to RIalpha subunit of cAMP-dependent protein kinase (GEM231) enhances therapeutic effectiveness of cancer chemotherapeutic agent irinotecan in nude mice bearing human cancer xenografts: in vivo synergistic activity, pharmacokinetics and host toxicity. Int J Oncol 21:73-80. 12063552
35. Wang H, Nan L, Yu D, Agrawal S, and Zhang R (2001) Antisense anti-MDM2 oligonucleotides as a novel therapeutic approach to human breast cancer: in vitro and in vivo activities and mechanisms. Clin Cancer Res 7:3613-3624. 11705884
36. Waters JS, Webb A, Cunningham D, Clarke PA, Raynaud F, di Stefano F, and Cotter FE (2000) Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J Clin Oncol 18:1812-1823. 10784621
37. Yuen AR, Halsey J, Fisher GA, Holmlund JT, Geary RS, Kwoh TJ, Dorr A, and Sikic BI (1999) Phase I study of an antisense oligonucleotide to protein kinase C-alpha (ISIS 3521/CGP 64128A) in patients with cancer. Clin Cancer Res 5:3357-3363. 10589745
38. Zamboni WC, Houghton PJ, Hulstein JL, Kirstein M, Walsh J, Cheshire PJ, Hanna SK, Danks MK, and Stewart CF (1999) Relationship between tumor extracellular fluid exposure to topotecan and tumor response in human neuroblastoma xenograft and cell lines. Cancer Chemother Pharmacol 43:269-276. 10071976
39. Zhang Q, Thomas SM, Xi S, Smithgall TE, Siegfried JM, Kamens J, Gooding WE, and Grandis JR (2004) SRC family kinases mediate epidermal growth factor receptor ligand cleavage, proliferation, and invasion of head and neck cancer cells. Cancer Res 64:6166-6173. 15342401